TET2 and cancer: Multiple gene mutations that contribute to cancer initiation and/or progression have been identified in myeloid leukaemia patients, among which missense mutations in the ten-eleven translocation 2 (TET2) oncogene, a member of the tet family, have been found in several independent patient cohorts with massive myeloproliferative disorders (1).